GSK and Moderna Settle Vaccine Patent Disputes

British drugmaker GSK and Moderna have settled lawsuits regarding patents for COVID-19 and RSV vaccines. The companies granted cross-licenses without any financial payments and asked a US court to dismiss the claims.

Xurve View
Thông tin chuyên sâu:
FILE PHOTO: GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/File Photo

GSK PLC-SPON ADR settled patent disputes with MODERNA INC on October 28, resolving allegations that Spikevax, mNEXSPIKE, and mResvia infringed its mRNA technology. The agreement spans courts in the United States and Europe without financial penalties.